

- **Name:** Te-Chun Hsia
 - **Current Position & Affiliation:** China Medical University Hospital
 - **Country:** Taiwan
-

• Educational Background:

- Master: Institute of Clinical Medicine, China Medical University
- PhD: Institute of Chinese Medicine, China Medical university

• Professional Experience:

- Fellowship: Veteran General Hospital, Taipei
- Training doctor: Hyperbaric Oxygen Therapy Center, Zingonia(Bergamo), Italy.
- Vice-chair, Department of Internal Medicine, China Medical University Hospital
- Chief, Respiratory intensive care unit; Intensive Medical Center; China Medical University Hospital(-01/MAY/2020)
- Chief, Hyperbaric Oxygen Therapy Center, China Medical University Hospital(1999-2014)
- Director and Associate Professor, Department of Respiratory Therapy, China Medical University

• Professional Organizations:

- Member of Council, Taiwan Lung Cancer Medical Society
- Chief, Member of Education Committee, Taiwan Lung Cancer Medical Society
- Director General, Taiwan Hyperbaric Oxygen and Undersea Medical Society(2020-)
- Member of Council, Taiwan Pulmonary and Critical Medical Society(2017-)
- Member of Education and Publication Committee, Taiwan Pulmonary and Critical Medical Society(2014-2017)
- Chief Editor of Education and Publication Committee, Taiwan Pulmonary and Critical Medical Society(2017-)
- Permanent Member of Council, Taiwan Integrated Medical Society
- Director General, Taiwan Integrated Medical Society(2017-)
- Director General, Respiratory Health Promotion Society, Taichung(-now)
- Director General, Asia-Pacific Chinese Medical Global union(2016-)
- Principal Investigator of Many Lung cancer IND, global trials
- Basic research in airway disease, lung cancer, SNP, cell line and cancer signal pathway

• Main Scientific Publications:

1. Tyrosine Kinase Inhibitor Activity in Patients with NSCLC Harboring Uncommon EGFR Mutations: A Retrospective International Cohort Study (UpSwinG)

Popat S, Hsia TC, Hung JY, Jung HA, Shih JY, Park CK, Lee SH, Okamoto T, Ahn HK, Lee YC, Sato Y, Lee SS, Mascaux C, Daoud H, Märten A, Miura S.

Oncologist. 2022 Apr 5;27(4):255-265. doi: 10.1093/oncolo/oyac022.PMID: 352747

2. An Observational Study on Treatment Outcomes in Patients With Stage III NSCLC in Taiwan: The KINDLE Study. Su PL,

Chang GC, Hsiao SH, Hsia TC, Lin MC, Lin MH, Shih JY, Yang CT, Yang SH, Chen YM.

JTO Clin Res Rep. 2022 Feb 8;3(3):100292. doi: 10.1016/j.jtocrr.2022.100292. eCollection 2022 Mar. PMID: 35252898

3. Association of Interleukin-8 Promoter Genotypes With Taiwan Lung Cancer Risk.

Li CH, Yang YC, Hsia TC, Shen TC, Shen YC, Chang WS, Wang YC, Tsai CW, Bau DT. *Anticancer Res.* 2022 Mar;42(3):1229-1236. doi: 10.21873/

*Anticanres.*15590.PMID: 35220213

4. Efficacy of Aumolertinib (HS-10296) in Patients With Advanced EGFR T790M+ NSCLC: Updated Post-National Medical Products Administration Approval Results From the APOLLO Registrational Trial.

Lu S, Wang Q, Zhang G, Dong X, Yang CT, Song Y, Chang GC, Lu Y, Pan H, Chiu CH, Wang Z, Feng J, Zhou J, Xu X, Guo R, Chen J, Yang H, Chen Y, Yu Z, Shiah HS, Wang CC, Yang N, Fang J, Wang P, Wang K, Hu Y, He J, Wang Z, Shi J, Chen S, Wu Q, Sun C, Li C, Wei H, Cheng Y, Su WC, Hsia TC, Cui J, Sun Y, Ou SI, Zhu VW, Chih-Hsin Yang JJ *Thorac Oncol.* 2022 Mar;17(3):411-422. doi: 10.1016/j.jtho.2021.10.024. Epub 2021 Nov 19. PMID: 34801749

5. Bisdemethoxycurcumin Induces Cell Apoptosis and Inhibits Human Brain Glioblastoma GBM 8401/Luc2 Cell Xenograft Tumor in Subcutaneous Nude Mice In Vivo.

Hsia TC, Peng SF, Chueh FS, Lu KW, Yang JL, Huang AC, Hsu FT, Wu RS.

Int J Mol Sci. 2022 Jan 4;23(1):538. doi: 10.3390/ijms23010538. PMID: 35008959

6. Efficacy of Prophylactic Traditional Chinese Medicine on Skin Toxicity of Afatinib in EGFR Mutation-Positive Advanced Lung Adenocarcinoma: A Single-Center, Prospective, Double-Blinded, Randomized-Controlled Pilot Trial.

Li CL, Hsia TC, Yang ST, Chao KC, Tu CY, Chen HJ, Li CH.

Integr Cancer Ther. 2022 Jan-Dec;21:15347354221086663. doi: 10.1177/15347354221086663. PMID: 35297709

7. Tetrandrine Suppresses Human Brain Glioblastoma GBM 8401/luc2 Cell-Xenografted Subcutaneous Tumors in Nude Mice In Vivo.

Liao CL, Ma YS, Hsia TC, Chou YC, Lien JC, Peng SF, Kuo CL, Hsu FT.

Molecules. 2021 Nov 24;26(23):7105. doi: 10.3390/molecules26237105. PMID: 34885686

8. Association of TIMP-2 Rs8179090 Genotypes With Lung Cancer Risk in Taiwan.

Liao WC, Huang CW, Hsia TC, Shen YC, Chang WS, Tsai CW, Wang YC, Yin MC, Bau DT.

Anticancer Res. 2021 Nov;41(11):5425-5430. doi: 10.2187/anticanres.15354. PMID: 34732411

9. Ergosta-7,9(11),22-trien-3 β -ol Attenuates Inflammatory Responses via Inhibiting MAPK/AP-1 Induced IL-6/JAK/STAT Pathways and Activating Nrf2/HO-1 Signaling in LPS-Stimulated Macrophage-like Cells.

Huang YP, Chen DR, Lin WJ, Lin YH, Chen JY, Kuo YH, Chung JG, Hsia TC, Hsieh WT.

Antioxidants (Basel). 2021 Sep 8;10(9):1430. doi: 10.3390/

*antiox*10091430. PMID: 34573062

10. Ouabain Suppresses Cell Migration and Invasion in Human Gastric Cancer AGS Cells Through the Inhibition of MMP Signaling Pathways.

Chen HY, Yang MD, Chou YC, Ma YS, Peng SF, Liao CL, Chen PY, Hsia TC, Lien JC, Chen CH.

Anticancer Res. 2021 Sep;41(9):4365-4375. doi:10.21873/anticanres.15241. PMID: 34475056

11. The Risk of Tuberculosis Infection in Non-dialysis Chronic Kidney Disease Patients.

Li CH, Chen HJ, Chen WC, Tu CY, Hsia TC, Hsu WH, Chang CT, Huang CC, Bau DT, Chou CY.

Front Med (Lausanne). 2021 Aug 13;8:715010. doi: 10.3389/fmed.2021.715010. eCollection 2021. PMID: 34485344

12. Pembrolizumab Plus Ipilimumab or Placebo for Metastatic Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score \geq 50%: Randomized, Double-Blind Phase III KEYNOTE-598 Study.

Boyer M, Şendur MAN, Rodríguez-Abreu D, Park K, Lee DH, Çiçin I, Yumuk PF, Orlandi FJ, Leal TA, Molinier O, Soparattanapaisarn N, Langleben A, Califano R, Medgyasszay B, Hsia TC, Otterson GA,

Xu L, Piperdi B, Samkari A, Reck M; KEYNOTE-598 Investigators.

J Clin Oncol. 2021 Jul 20;39(21):2327-2338. doi: 10.1200/JCO.20.03579. Epub 2021 Jan 29. PMID: 33513313

13. The Effectiveness and Safety of Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer Patients With Stage III/IV: A Multicenter Study

Hsu JC, Nguyen PA, Chen YT, Yang SC, Lin CC, Yang YH, Lin YC, Hsia TC, Hsieh HC, Wu JS, Chang CP, Feng YH, Lin PC, Hsu PC, Tzeng HE, Chien SC, Chang WC, Chang CC, Yang HC, Lee CM, Lu CY.

Front Oncol. 2021 Jul 7;11:671127. doi: 10.3389/fonc.2021.671127. eCollection 2021. PMID: 34307141

14. Significant Association of Cyclin D1 Promoter Genotypes With Asthma Susceptibility in Taiwan

Li CH, Chiu KL, Hsia TC, Shen TC, Chen LH, Yu CC, Mong MC, Chang WS, Tsai CW, Bau DT.

In Vivo. 2021 Jul-Aug;35(4):2041-2046. doi: 10.21873/invivo.12473. PMID: 34182479

15. PKC δ -mediated SGLT1 upregulation confers the acquired resistance of NSCLC to EGFR TKIs

Chen CH, Wang BW, Hsiao YC, Wu CY, Cheng FJ, Hsia TC, Chen CY, Wang Y, Weihua Z, Chou RH, Tang CH, Chen YJ, Wei YL, Hsu JL, Tu CY, Hung MC, Huang WC.

Oncogene. 2021 Jul;40(29):4796-4808. doi: 10.1038/s41388-021-01889-0. Epub 2021 Jun 21. PMID: 34155348

16. The relative importance of predictive factors for single first-generation EGFR-TKI use for more than 5 years in patients with advanced non-small cell lung cancer: Taiwan multicenter TIPS-5 study

Huang YH, Hung JY, Ko HW, Su PL, Lai CL, Chang HC, Hsia TC, Lin SH, Wu KL, Yang CT, Su WC, Chu YC, Wang CC, Liao WY, Lin YT, Lin CH, Lin MC, Hsu KH, Tseng JS, Yang TY, Chen KC, Lee MH, Yu SL, Ho CC, Chang GC.

Ther Adv Med Oncol. 2021 May 22;13:17588359211018022. doi: 10.1177/17588359211018022. eCollection 2021. PMID: 34093743

17. Interaction of DNA Repair Gene XPC With Smoking and Betel Quid Chewing Behaviors of Oral Cancer

Wu CN, Chang WS, Shih LC, Wang YC, Lee HT, Yu CC, Wang ZH, Mong MC, Hsia TC, Tsai CW, Bau DT.

Cancer Genomics Proteomics. 2021 May-Jun;18(3 Suppl):441-449. doi: 10.21873/cgp.20270. PMID: 33994366

18. Genistein enhances the effects of L-asparaginase on inducing cell apoptosis in human leukemia cancer HL-60 cells

Hsiao YC, Chueh FS, Ma YS, Lien JC, Hsia TC, Huang WW, Chou YC, Chen PY, Chung JG, Chen HY, Liu KC.

Environ Toxicol. 2021 May;36(5):764-772. doi: 10.1002/tox.23078. Epub 2020 Dec 21. PMID: 33347704

19. Lung Cancer in Republic of China.

Luo YH, Chiu CH, Scott Kuo CH, Chou TY, Yeh YC, Hsu HS, Yen SH, Wu YH, Yang JC, Liao BC, Hsia TC, Chen YM.

J Thorac Oncol. 2021 Apr;16(4):519-527. doi: 10.1016/j.jtho.2020.10.155. PMID: 33781442

20. Ceritinib Efficacy and Safety in Treatment-Naive Asian Patients With Advanced ALK-Rearranged NSCLC: An ASCEND-4 Subgroup Analysis

Tan DSW, Geater S, Yu CJ, Tsai CM, Hsia TC, Chen J, Lin MC, Lu Y, Sriuranpong V, Yang CT, Sen P, Branle F, Shi M, Wu YL

JTO Clin Res Rep. 2020 Dec 17;2(3):100131. doi: 10.1016/j.jtocrr.2020.100131. eCollection 2021 Mar. PMID: 34589995